Pfizer’s Immunology Strategy Expands to In Vivo Cell Therapy With Starna Deal
Pfizer gains global rights, excluding Greater China, to three in vivo CAR-T cell therapies from Starna Therapeutics in preclinical development for undisclosed autoimmune diseases. It’s the latest in a series of big pharma business deals involving in vivo cell therapy assets and platform technologies.